Summary

Requires HHS to quickly begin rulemaking to set most-favored-nation style price targets so U.S. patient prices for prescription drugs are comparable to prices in similarly developed countries. Directs HHS to certify whether individual drug importation is safe and saves money, asks DOJ and the FTC to pursue antitrust enforcement against pharma conduct, and orders Commerce and USTR to study whether manufacturer practices harm national security or force U.S. patients to subsidize global drug R&D. Also directs HHS to facilitate direct-to-consumer purchasing programs for manufacturers that comply with the price targets. The bill sets a 30‑day timeline for HHS to propose its rulemaking plan and calls for several interagency actions and studies rather than immediate funding changes.

• HHS must propose within 30 days a plan to set most-favored-nation style price targets tying U.S. patient drug prices to similarly developed countries.
• HHS must certify whether individual drug importation is safe and yields significant cost savings and outline waiver conditions for case-by-case importation.
• DOJ and FTC leaders are directed to pursue antitrust enforcement against pharmaceutical manufacturers where appropriate.
• HHS is instructed to facilitate direct-to-consumer purchasing programs for manufacturers that follow the price targets.
• Commerce and the USTR must study whether manufacturer practices harm national security or unfairly shift R&D costs to U.S. patients or distort foreign markets.
• The bill sets regulatory and study requirements for multiple federal agencies but does not allocate new appropriations.
• Provisions could prompt rulemaking, enforcement actions, interagency reports, and potential international or legal disputes.
• Focus is on changing pricing and market behavior through regulation and enforcement rather than changing entitlement or benefit structures.